p53 Antibody (2Q366): sc-71818

p53 Antibody (2Q366), part of the Santa Cruz Biotechnology’s p53 monoclonal antibody collection, is designed to detect the conserved, denaturation-resistant p53 protein in mouse, rat, and human samples. This highly specific p53 monoclonal antibody IgG2b (2Q366) is raised against amino acids 370-378 of the p53 protein and is compatible with key laboratory techniques such as western blotting, immunoprecipitation, immunofluorescence, and flow cytometry. Conveniently available, conjugated to phycoerythrin or fluorescein isothiocyanate, anti-p53 antibody (2Q366) is ideal for use in immunohistochemistry on paraffin-embedded tissues, flow cytometry, and other fluorescence-based applications. The p53 protein is a crucial tumor suppressor encoded by the TP53 gene on chromosome 17p13.1. p53 regulates cell cycle arrest, DNA repair, apoptosis, and cellular senescence in response to cellular stress, thereby preventing tumor formation. p53’s structure includes several domains such as the Transactivation Domain (TAD), DNA-Binding Domain (DBD), Oligomerization Domain (OD), and Regulatory Domain, which are essential for its tumor-suppressing activities. Mutations in the TP53 gene are among the most common in human cancers, found in over half of all tumors. These mutations typically affect the DNA-binding domain, preventing p53 from regulating target genes, which leads to unchecked cell proliferation. TP53 mutation status is a key diagnostic marker in various cancers, including breast, lung, and colorectal cancer. SCBT’s p53 monoclonal antibodies are crucial in cancer research, offering reliable detection for use in diagnostics and therapeutic research targeting p53 pathways. Therapies aimed at restoring p53 function, including gene therapy, small molecule drugs, and immunotherapies, continue to show promise for cancer treatment. Understanding p53 mutations and regulatory mechanisms remains critical for advancing cancer diagnosis and therapy.

The preferred p53 antibody is p53 Antibody (DO-1): sc-126.